AviadoBio

AviadoBio is a biotechnology startup based in the United Kingdom, founded in 2019, with a focus on revolutionizing gene therapy for neurodegenerative disorders. The company's slogan "A revolution in gene therapy for neurodegenerative disorders" reflects its commitment to translating groundbreaking science and precision delivery into life-changing medicines for individuals battling frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). AviadoBio's innovative approach is rooted in its deep understanding of the brain and its suite of proprietary gene therapy platforms and delivery technologies. The company is dedicated to addressing the challenges of ensuring precise drug delivery, aiming to maximize the therapeutic potential of gene therapy to potentially halt or even reverse neurodegenerative diseases. This pioneering work is based on research from King’s College London and the UK Dementia Research Institute, showcasing the scientific foundation of the company's efforts. In October 8, 2024, AviadoBio secured a significant $20.00M investment in a Corporate Round, with Astellas Pharma participating as the investing entity. This funding injection underlines the growing interest and support for AviadoBio's mission to develop groundbreaking treatments for neurodegenerative disorders.